3,4-dihydroxyphenylacetic acid inhibits inflammation and repairs the intestinal barrier dysfunction in mice with type 2 diabetes by inhibiting the activation of JNK and p38 (173). The gene discussed is MAPK8; the disease is type 2 diabetes mellitus.